Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma

Multiple myeloma (MM) is the second most common hematological malignancy, characterized by an abnormal accumulation of plasma cells in the bone marrow. Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of multiple genes to regulate various principal biological functions, for example, cell proliferation and survival, stemness, inflammation and immune responses. Aberrant STAT3 activation has been identified as a key driver of tumorigenesis in many types of cancers, including MM. Herein, we summarize the current evidence for the role of STAT3 in affecting cancer hallmark traits by: (1) sustaining MM cell survival and proliferation, (2) regulating tumor microenvironment, (3) inducing immunosuppression. We also provide an update of different strategies for targeting STAT3 in MM with special emphasis on JAK inhibitors that are currently undergoing clinical trials. Finally, we discuss the challenges and future direction of understanding STAT3 signaling in MM biology and the clinical development of STAT3 inhibitors.

Automated summary

This article summarizes the role of STAT3 in multiple myeloma (MM), including its involvement in cell survival and proliferation, regulation of the tumor microenvironment, and induction of immunosuppression. The article also provides updates on different strategies for targeting STAT3 in MM, with a focus on JAK inhibitors currently undergoing clinical trials. Finally, the challenges and future directions of understanding STAT3 signaling and developing STAT3 inhibitors in MM are discussed.